Company intelligence / Profile preview

EndoGastric Solutions

Redmond, Washington, United Statesendogastricsolutions.com ↗

Ownership: Private
Development stage: Commercial

Overview

EndoGastric Solutions developed and commercialized the EsophyX device and TIF® procedure for incisionless surgical treatment of GERD. The technology has been FDA-cleared since 2007 and CE-marked since 2006. Over 30,000 procedures have been performed globally. Clinical data show that more than 80% of patients can discontinue daily proton pump inhibitors after the procedure with a lower side-effect profile compared to traditional surgery[2][6]. In July 2024, the company was acquired by Merit Medical Systems[3].

Therapeutic areas: Gastroenterology
Modalities: DeviceNon-pharmacological therapy
Industry: Surgical Medical Devices

Beyond the preview

Go deeper on EndoGastric Solutions.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EndoGastric Solutions.

Explore the full profile